DOCSLIB.ORG

Immune Regulation by CD52-Expressing CD4 T Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immune Regulation by CD52-Expressing CD4 T Cells Cellular & Molecular Immunology (2013) 10, 379–382 ß 2013 CSI and USTC. All rights reserved 1672-7681/13 $32.00 www.nature.com/cmi RESEARCH HIGHLIGHT Immune regulation by CD52-expressing CD4 T cells Ban-Hock Toh1, Tin Kyaw1,2, Peter Tipping1 and Alex Bobik2 T-cell regulation by CD52-expressing CD4 T cells appears to operate by two different and possibly synergistic mechanisms. The first is by its release from the cell surface of CD4 T cells that express high levels of CD52 that then binds to the inhibitory sialic acid-binding immunoglobulin-like lectins-10 (Siglec-10) receptor to attenuate effector T-cell activation by impairing phosphorylation of T-cell receptor associated lck and zap-70. The second mechanism appears to be by crosslinkage of the CD52 molecules by an as yet unidentified endogenous ligand that is mimicked by a bivalent anti-CD52 antibody that results in their expansion. Cellular & Molecular Immunology (2013) 10, 379–382; doi:10.1038/cmi.2013.35; published online 12 August 2013 he immune system is designed to appears in the affirmative, and includes suppression was lost by cleavage of N- T protect its host from invading players such as IL-10-secreting Tr1 and glycans from CD52-Fc by peptide N- pathogens and yet remain non-reactive TGF-b-secreting Th3. cells. Absence of glycosidase or by removal of sialic acid to self. Immunological homeostasis is surface markers limited the usefulness residues by neuraminidase. Suppression maintained by purging self-reactive lym- of these other regulators. However, the was also blocked by antibody to the phocytes by clonal deletion coupled with recent report that CD49b and lympho- extracellular domain of Siglec-10 and a regulatory population of lymphocytes cyte activation gene-3 are highly and sta- by soluble Siglec-10-Fc. Given that that suppress self-reactive lymphocytes bly coexpressed by human and mouse Siglec-10 contain two immunoreceptor that have ‘escaped’ clonal deletion. Tr1 has provided an approach for studies tyrosine-based inhibition motifs, it Disruption of the delicate balance of of IL-10-secreting Tr1 cells.2 seems likely that recruitment of SHP regulatory and effector lymphocytes, is Yet another T-cell regulator has phosphatases by these motifs impaired thought to be a major contributor to recently gained prominence by a recent phosphorylation of Lck and Zap-70. the development of autoimmune dis- report in Nature Immunology of CD4 T The observation of a lower frequency ease. Pioneering studies of Shimon cells expressing high levels of CD52.3 and impaired function of these regula- Sakaguchi have led to the firm estab- CD52 is a short peptide of 12 amino tors in human type 1 diabetes coupled lishment of CD251Foxp3 expressing acids in humans linked at its C-terminus with the aggravated diabetes following CD4 T lymphocytes as fundamental for to a glycosylphosphatidylinositol (GPI) transfer of lymphocytes deleted of this immune homeostasis as the loss of this anchor. Its single N-glycosylation site is population suggest that these may pro- population results in intractable auto- occupied by large sialylated polylactossa- tect from the development of auto- immune disease in man and mouse.1 mine on a tetra-antennary fucosylated immune disease. While a loss of The transcription factor Foxp3 plays a mannose core.4 Suppression appears to function of CD52 was demonstrated in key role in their development. These cells be mediated by soluble CD52, released the mouse model of type 1 diabetes, a are a distinct CD4 T-cell lineage that from its GPI anchor by phospholipase gain of function with augmented CD52 arise in the thymus, but can also be gen- C, which then binds to inhibitory sialic ameliorating disease was not explored. erated in the periphery. acid-binding immunoglobulin-like lec- Also endogenous molecular mechanisms But are there other players in main- tins-10 (Siglec-10) receptor to inhibit that activate cleavage of the GPI anchor taining T-cell homeostasis? The answer T-cell activation by impairing phosphor- of CD52 to release it in soluble form ylation of T-cell receptor associated remains unknown. 1Centre for Inflammatory Diseases, Department kinases Lck and Zap70 (Figure 1). Siglec-10 was cloned from a human of Medicine, Southern Clinical School, Faculty of Siglec-10 belongs to a major subfamily dendritic cell library in 20017 and was Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia and 2Vascular of Ig-like lectins that mediate sialic acid also identified by database mining of an 8 Biology and Atherosclerosis Laboratory, Baker recognition by their terminal Ig like asthmatic eosinophil EST library. It is IDI Heart and Diabetes Institute, Melbourne, domains5 to regulate innate and adaptive expressed in peripheral blood mononuc- Vic., Australia 6 Correspondence: Ban-Hock Toh immune responses. The data suggest lear cells including monocytes, dendritic E-mail: [email protected] that sialic acid structures of CD52 binds cells and B lymphocytes. Given its broad Received: 1 July 2013; Accepted: 2 July 2013 to Ig-like domain of Siglec-10 because immune distribution, suppression by Research Highlight 380 CD52 CD52 Siglec-10 Phospholipase P Zap 70 CD52hiCD52 hi CD4+ T cell CD52low LCK CD4+ T cells TCR Figure 1 T-cell regulation by soluble CD52 binding to Siglec-10. CD52 release from its GPI anchor by phospholipase binds via its terminal sialic acid domain to the terminal Ig domain of Siglec-10. Phosphatase activation by the ITIM motifs of Siglec-10 impairs phosphorylation of T-cell receptor associated lck and zap70. GPI, glycosylphosphatidylinositol; ITIM, immunoreceptor tyrosine-based inhibition motif; Siglec-10, sialic acid- binding immunoglobulin-like lectins-10. CD52 released from CD52-expressing stimulation.12 Co-injection of regulatory conventional CD4 T cells and there are regulatory CD4 T cells may not be T cells expanded in culture by IL-2 multiple isoforms of this molecule, it has restricted to T cells only, but may also and anti-CD52 suppressed lethal graft been suggested that the antibody that extend to a broader population of peri- vs. host disease in severe combined costimulates regulatory T-cell expansion pheral blood mononuclear cells that immunodeficiency disorder recipients may bind to an epitope preferentially include dendritic cells, monocytes and caused by human peripheral blood expressed on regulatory T cells. B lymphocytes. As human Siglec-10 also mononuclear cells. As 4C8 is an IgG3 CD52-expressing CD4 T cells differ binds to vascular adhesion protein-1 to monoclonal antibody, it probably acts from CD251Foxp31 regulatory CD4 T act as its substrate and to mediate as a costimulator by crosslinking CD52 cells in a number of important aspects. lymphocyte binding to the endothe- molecules on the cell surface, to expand It differs in its distribution in that CD52 lium,9 binding of CD52 to siglec-10 CD4 T cells that suppresses in a contact- is also found in sperm as its major matu- could also potentially modify the inflam- dependent manner (Figure 2). The epi- ration-associated membrane protein.16 matory microenvironment. tope for this antibody as with the It is also more widely distributed in the The CD52 story may be even more CAMPATH antibody13 likely lies on an immune system as it is expressed by all complex than revealed by the above stu- amino-acid sequence proximal to the lymphocytes, monocytes and dendritic dies. Earlier reports suggest that CD52 terminal sialic acids that bind to the ter- cells.17,18 It is also expressed by eosino- recognized by monoclonal antibody minal Ig domain of Siglec-10. A natural phils but not by neutrophils.18 Despite its 4C8 can also act as a novel costimulatory ligand that crosslinks CD52 remains expression in lymphocytes and sperm molecule for the induction of CD4 re- unknown. Nonetheless the situation here and the report that the N-glycans of a gulatory T cells. The 4C8 IgG3 monoclo- is analogous to the costimulatory expan- CD52 isoform is associated with human nal antibody was first reported for its sion of CD41Foxp31 regulatory T cells infertility,19 CD52 gene knockout gene- capacity to inhibit the post-adhesive by monoclonal antibody to the tumor- rates no discernable phenotype in the transendothelial migration of T cells necrosis factor (TNF) receptor super- immune and reproductive systems.20 through human endothelial cell mono- family member 25 that is constitutively This stands in contrast to the fatal auto- layers.10 In a subsequent study, CD4 T and highly expressed by these regulatory immune disease phenotype arising from cells expanded by stimulation with T cells.14 The expansion, dependent on the phenotype arising from knockout of anti-CD3 and costimulation with anti- T-cell receptor engagement with MHC CD2521 or of the Foxp3 transcriptional 4C8 expressed high levels of IL-2 that class II antigen, prevents allergic lung regulator.1,22 The developmental path- suppressed in a contact-dependent man- inflammation. The TNF receptor super- way of these T cells in the thymus and/ ner.11 The suppressor cells were shown to family member 25 ligand in this instance or in the periphery is also not known. develop from CD41CD252CD45RO1 has been identified as sTLIA, the con- CD52 is also the molecular target of precursor cells. These anti-CD52 stitutive expression of which in trans- CAMPATH-1, a rat monoclonal anti- induced regulatory T cells suppressed genic mice expands these regulatory T body raised against human lymphocyte proliferation of CD4 and CD8 T cells cells.15 Given that TNF receptor super- proteins by Hermann Waldmann in the provided with polyclonal or allogeneic family member 25 is also expressed on Cambridge Pathology Department.23 Cellular & Molecular Immunology Research Highlight 381 Characterization of the 4C8 antigen involved in transendothelial migration of CD26hi T CD52 cells after tight adhesion to human umbilical 4C8 mAb vein endothelial cell monolayers.
Load more

Recommended publications
  • New Insights Into Epididymal Function in Relation to Sperm Maturation
    REPRODUCTIONREVIEW New insights into epididymal function in relation to sperm maturation Jean-Louis Dacheux and Franc¸oise Dacheux UMR INRA-CNRS 7247, 37380 Nouzilly, France Correspondence should be addressed to J-L Dacheux; Email: [email protected] Abstract Testicular spermatozoa acquire fertility only after 1 or 2 weeks of transit through the epididymis. At the end of this several meters long epididymal tubule, the male gamete is able to move, capacitate, migrate through the female tract, bind to the egg membrane and fuse to the oocyte to result in a viable embryo. All these sperm properties are acquired after sequential modifications occurring either at the level of the spermatozoon or in the epididymal surroundings. Over the last few decades, significant increases in the understanding of the composition of the male gamete and its surroundings have resulted from the use of new techniques such as genome sequencing, proteomics combined with high-sensitivity mass spectrometry, and gene-knockout approaches. This review reports and discusses the most relevant new results obtained in different species regarding the various cellular processes occurring at the sperm level, in particular, those related to the development of motility and egg binding during epididymal transit. Reproduction (2014) 147 R27–R42 Introduction sequentially throughout the epididymis. In view of these two parallel events, most investigations have The formation of fertile spermatozoa is the result of involved assessing the relationships between these two spectacular stages of cell differentiation that begin in events and identifying the epididymal signals able to the male gonad and finish in the female tract. The control spermatozoon fertility.
    [Show full text]
  • USAN Naming Guidelines for Monoclonal Antibodies |
    Monoclonal Antibodies In October 2008, the International Nonproprietary Name (INN) Working Group Meeting on Nomenclature for Monoclonal Antibodies (mAb) met to review and streamline the monoclonal antibody nomenclature scheme. Based on the group's recommendations and further discussions, the INN Experts published changes to the monoclonal antibody nomenclature scheme. In 2011, the INN Experts published an updated "International Nonproprietary Names (INN) for Biological and Biotechnological Substances—A Review" (PDF) with revisions to the monoclonal antibody nomenclature scheme language. The USAN Council has modified its own scheme to facilitate international harmonization. This page outlines the updated scheme and supersedes previous schemes. It also explains policies regarding post-translational modifications and the use of 2-word names. The council has no plans to retroactively change names already coined. They believe that changing names of monoclonal antibodies would confuse physicians, other health care professionals and patients. Manufacturers should be aware that nomenclature practices are continually evolving. Consequently, further updates may occur any time the council believes changes are necessary. Changes to the monoclonal antibody nomenclature scheme, however, should be carefully considered and implemented only when necessary. Elements of a Name The suffix "-mab" is used for monoclonal antibodies, antibody fragments and radiolabeled antibodies. For polyclonal mixtures of antibodies, "-pab" is used. The -pab suffix applies to polyclonal pools of recombinant monoclonal antibodies, as opposed to polyclonal antibody preparations isolated from blood. It differentiates polyclonal antibodies from individual monoclonal antibodies named with -mab. Sequence of Stems and Infixes The order for combining the key elements of a monoclonal antibody name is as follows: 1.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • Constitutive Expression of Murine Ctla4ig from a Recombinant Adenovirus Vector Results in Prolonged Transgene Expression
    Gene Therapy (1997) 4, 853–860 1997 Stockton Press All rights reserved 0969-7128/97 $12.00 Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression DB Schowalter1, L Meuse1, CB Wilson2,3, PS Linsley4 and MA Kay1,2,5,6 1Division of Medical Genetics, Department of Medicine, and Departments of 2Pediatrics, 3Immunology, 6Biochemistry and 5Pathology, University of Washington; and 4Bristol-Myers Squibb Pharmaceuticals, Seattle, WA, USA The administration of soluble muCTLA4Ig around the time Ad.RSV-muCTLA4Ig and a reporter adenovirus (2 × 109 of adenovirus vector mediated gene transfer into murine p.f.u. of Ad.PGK-hAAT) resulted in prolonged reporter hepatocytes has been shown to markedly prolong trans- gene expression, reduced anti-adenovirus and anti-hAAT gene expression, diminish the formation of adenovirus antibody production, and attenuated T cell proliferation and neutralizing antibody, decrease T cell proliferative IFN-g production in response to adenoviral vector. Mice response and infiltration into the liver without causing irre- given a constant total amount of adenovirus with dimin- versible systemic immunosuppression. In this study, an ishing amounts of Ad.RSV-muCTLA4Ig and a constant E1/E3-deleted adenovirus vector constitutively expressing amount of reporter virus (2 × 109 p.f.u. of Ad.PGK-hAAT) murine CTLA4Ig (Ad.RSV-muCTLA4Ig) was constructed in demonstrated prolonged reporter gene expression and order to determine if production of muCTLA4Ig from within decreased anti-adenovirus and anti-hAAT antibody pro- transduced cells (ie hepatocytes) would provide a more duction only when high serum levels of muCTLA4Ig were specific/localized interference with the CD28/B7–1 and produced.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,120,766 Hale Et Al
    USOO612O766A United States Patent (19) 11 Patent Number: 6,120,766 Hale et al. (45) Date of Patent: Sep.19, 2000 54) CDW52-SPECIFIC ANTIBODY FOR 56) References Cited TREATMENT OF MULTIPLE SCLEROSIS U.S. PATENT DOCUMENTS 76 Inventors: Geoffrey Hale; Herman Waldmann, 5,545,403 8/1996 Page ..................................... 424/133.1 both of University of Cambridge, 5,545.404 8/1996 Page et al. ... 424/133.1 Department of Pathology, Immunology 5,545,405 8/1996 Page ..................................... 424/133.1 Div., Tennis Court Road, Cambridge, FOREIGN PATENT DOCUMENTS CB210P, United Kingdom O3284.04 8/1989 European Pat. Off.. 21 Appl. No.: 08/244,316 3284.04 8/1989 European Pat. Off. ... A61K 39/395 22 PCT Filed: Dec. 4, 1992 OTHER PUBLICATIONS 86 PCT No.: PCT/GB92/02252 Riechmann et al., “Reshaping human antibodies for therapy”, Nature 322:323-327 (1988). S371 Date: Jun. 22, 1994 Page et al., “High Level Expression of the Humanized Monoclonal Antibody Campath-1H in Chinese Hamster S 102(e) Date: Jun. 22, 1994 Ovary Cells”, Bio/Technology 9:64–68 (1991). 87 PCT Pub. No.: WO93/10817 Myers, L.W. et al., Clinical Neuropharmacology, 8(1):119-141, Feb. 1990. PCT Pub. Date:Jun. 10, 1993 Beer, S. et al, Schweiz. Med. Wschr, 121:961–969, 1991. 30 Foreign Application Priority Data Weber et al, J of Neuro. vol. 22:1-9 (1989). Dec. 4, 1991 GB United Kingdom ................... 9125768 Primary Examiner-Christopher L. Chin Attorney, Agent, or Firm Kubovcik & Kubovcik (51) Int. Cl." ................................................... A61K 39/395 57 ABSTRACT 52 U.S. Cl.
    [Show full text]
  • A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
    Cancer Therapy: Preclinical A Novel Raji-Burkitt’s Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents Rosa Lapalombella,1Xiaobin Zhao,1, 2 Georgia Triantafillou,1Bo Yu,3,4 Yan Jin, 4 Gerard Lozanski,5 Carolyn Cheney,1Nyla Heerema,5 David Jarjoura,6 Amy Lehman,6 L. James Lee,3,4 Guido Marcucci,1Robert J. Lee,2,4 Michael A. Caligiuri,1 Natarajan Muthusamy,1and John C. Byrd1, 2 Abstract Purpose:Todate, efforts to study CD52-targeted therapies, such as alemtuzumab, have beenlim- ited due to the lack of stable CD52 expressing transformed B-cell lines and animal models.We describe generation and utilization of cell lines that stably express CD52 both in vitro and in vivo. Experimental Design: By limiting dilution, we have established several clones of Raji-Burkitt’s lymphoma cell line that express surface CD52. Immunophenotype and cytogenetic charac- terizationof these clones was done. In vivo usefulness of the CD52high cell line to evaluate the ther- apeuticefficacyofCD52-directedantibody wasinvestigatedusingaSCIDmousexenograftmodel. Results: Stable expression of CD52 was confirmed in cells cultured in vitro up to 52 weeks of continuous growth. The functional integrity of the expressed CD52 molecule was shown using alemtuzumab, which induced cytotoxic effects in vitro in the CD52high but not the CD52low clone. Compared with control antibody, alemtuzumab treatment in CD52high inoculated mice resulted in significantly increased median survival. Comparable levels of CD52-targeted direct cyto- toxicity, complement-dependent cytotoxicity, and antibody-dependent cytotoxicity and anti-CD52 immunoliposome-mediated delivery of synthetic oligodeoxyribo nucleotides in CD52high clone and primary B-chronic lymphocytic leukemia cells implicated potential in vivo application of this model for evaluation of CD52-targeted antibody and immunoliposomes encapsulating therapeutic agents.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • In Antithymocyte and Antilymphocyte Globulin: Possible Role for the Expansion of GPI-AP Deficient Cells in Aplastic Anemia Heike H
    Antibodies to glycosylphosphatidyl-inositol anchored proteins (GPI-AP) in antithymocyte and antilymphocyte globulin: possible role for the expansion of GPI-AP deficient cells in aplastic anemia Heike H. Breitinger, Markus T. Rojewski, Hubert Schrezenmeier To cite this version: Heike H. Breitinger, Markus T. Rojewski, Hubert Schrezenmeier. Antibodies to glycosylphosphatidyl- inositol anchored proteins (GPI-AP) in antithymocyte and antilymphocyte globulin: possible role for the expansion of GPI-AP deficient cells in aplastic anemia. Annals of Hematology, Springer Verlag, 2009, 88 (9), pp.889-895. 10.1007/s00277-008-0688-0. hal-00535024 HAL Id: hal-00535024 https://hal.archives-ouvertes.fr/hal-00535024 Submitted on 11 Nov 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Ann Hematol (2009) 88:889–895 DOI 10.1007/s00277-008-0688-0 ORIGINAL ARTICLE Antibodies to glycosylphosphatidyl-inositol anchored proteins (GPI-AP) in antithymocyte and antilymphocyte globulin: possible role for the expansion of GPI-AP deficient cells in aplastic anemia Heike H. Breitinger & Markus T. Rojewski & Hubert Schrezenmeier Received: 19 September 2008 /Accepted: 18 December 2008 /Published online: 13 January 2009 # Springer-Verlag 2009 Abstract Antithymocyte globulin (ATG) and antilymphocyte immunosuppressive effects in treatment of aplastic anemia.
    [Show full text]
  • CD20-TCB with Obinutuzumab Pretreatment As Next-Generation
    Published OnlineFirst May 1, 2018; DOI: 10.1158/1078-0432.CCR-18-0455 Translational Cancer Mechanisms and Therapy Clinical Cancer Research CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies Marina Bacac1, Sara Colombetti1, Sylvia Herter1, Johannes Sam1, Mario Perro1, Stanford Chen1, Roberta Bianchi1, Marine Richard1, Anne Schoenle1, Valeria Nicolini1, Sarah Diggelmann1, Florian Limani1, Ramona Schlenker1, Tamara Husser€ 1, Wolfgang Richter2, Katharine Bray-French2, Heather Hinton1, Anna Maria Giusti1, Anne Freimoser-Grundschober1, Laurent Lariviere3, Christiane Neumann1, Christian Klein1, and Pablo Umana~ 1 Abstract Purpose: Despite promising clinical activity, T-cell–engag- considerably higher potency than other CD20-TCB antibo- ing therapies including T-cell bispecific antibodies (TCB) are dies in clinical development and is efficacious on tumor associated with severe side effects requiring the use of step-up- cells expressing low levels of CD20. CD20-TCB also displays dosing (SUD) regimens to mitigate safety. Here, we present a potent activity in primary tumor samples with low effector: next-generation CD20-targeting TCB (CD20-TCB) with signif- target ratios. In vivo, CD20-TCB regresses established tumors icantly higher potency and a novel approach enabling safer of aggressive lymphoma models. Gpt enables profound administration of such potent drug. B-cell depletion in peripheral blood and secondary lym- Experimental Design: We developed CD20-TCB based on phoid organs and reduces T-cell activation and cytokine the 2:1 TCB molecular format and characterized its activity release in the peripheral blood, thus increasing the safety of preclinically. We also applied a single administration of obi- CD20-TCB administration. Gpt is more efficacious and safer nutuzumab (Gazyva pretreatment, Gpt; Genentech/Roche) than SUD.
    [Show full text]
  • Notch Signaling Deregulation in Multiple Myeloma: a Rational Molecular Target
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 29 Notch signaling deregulation in multiple myeloma: A rational molecular target Michela Colombo1,*, Serena Galletti2,*, Silvia Garavelli1, Natalia Platonova2, Alessandro Paoli1, Andrea Basile1, Elisa Taiana2, Antonino Neri2, Raffaella Chiaramonte1 1Department of Health Sciences, Università degli Studi di Milano, 20142 Milano, Italy. 2 Department of Clinical Sciences and Community Health, Università degli Studi di Milano; Hematology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milano, Italy. *These authors have contributed equally to this work Correspondence to: Antonino Neri, e-mail: [email protected] Raffaella Chiaramonte, e-mail: [email protected] Keywords: Notch, multiple myeloma, molecular, therapy Received: May 19, 2015 Accepted: August 03, 2015 Published: August 13, 2015 ABSTRACT Despite recent therapeutic advances, multiple myeloma (MM) is still an incurable neoplasia due to intrinsic or acquired resistance to therapy. Myeloma cell localization in the bone marrow milieu allows direct interactions between tumor cells and non- tumor bone marrow cells which promote neoplastic cell growth, survival, bone disease, acquisition of drug resistance and consequent relapse. Twenty percent of MM patients are at high-risk of treatment failure as defined by tumor markers or presentation as plasma cell leukemia. Cumulative evidences indicate a key role of Notch signaling in multiple myeloma onset and progression. Unlike other Notch- related malignancies, where the majority of patients carry gain-of-function mutations in Notch pathway members, in MM cell Notch signaling is aberrantly activated due to an increased expression of Notch receptors and ligands; notably, this also results in the activation of Notch signaling in surrounding stromal cells which contributes to myeloma cell proliferation, survival and migration, as well as to bone disease and intrinsic and acquired pharmacological resistance.
    [Show full text]
  • CLL/Mantle Cell Companion Add-On Flow Panel
    CLL/Mantle Cell Companion Add-On Flow Panel Methodology Flow Cytometry Test Description Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD3, CD5, CD19, CD22, CD36, CD43, CD45, CD52, CD200, and FMC7 (10 markers). This panel is not for detection of minimal residual disease. Clinical Significance This panel is helpful in differentiating CLL from MCL; in small CD10+ lymphoma (usually negative for CD43) versus large cell lymphoma and Burkitt's (40-60%+); in B-ALL vs. mature CD10+ lymphoma, especially in surface light chain negative cases; in HCL screening (extremely useful in rare CD5+ HCL cases); for evaluating heme versus nonheme cases (along with CD45) in ALCL, especially Null phenotype; and for granulocytic sarcomas (not all granulocytic sarcomas are CD34+, especially monocytic). CD43 is useful in identifying the myeloid/monocyte populations (e.g. myeloid sarcomas) and immature B cells. CD43 is also useful as an additional T-cell antigen for aberrant loss in T-cell lymphomas, NK cell antigen (e.g. CD3-CD43+), and in mature B-cell non-Hodgkin lymphomas, especially CLL/MCL (usually CD43+), FCL (usually CD43-) and HCL (usually CD43-). In combination with CD11c (part of our main panel), FMC7 and CD200 are extremely useful in separating CLL (including atypical CLL) from MCL by flow. Specimen Requirements Flow cytometry testing can be performed on bone marrow aspirate, peripheral blood, fresh bone marrow core biopsy, unfixed tissue, and body fluids. Please see full specimen requirements for either Standard Leukemia/Lymphoma Analysis or Extended Leukemia/Lymphoma Analysis as this add-on panel is available in combination with either of those full panels.
    [Show full text]
  • Monoclonal Antibodies As Neurological Therapeutics
    pharmaceuticals Review Monoclonal Antibodies as Neurological Therapeutics Panagiotis Gklinos 1 , Miranta Papadopoulou 2, Vid Stanulovic 3, Dimos D. Mitsikostas 4 and Dimitrios Papadopoulos 5,6,* 1 Department of Neurology, KAT General Hospital of Attica, 14561 Athens, Greece; [email protected] 2 Center for Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 11527 Athens, Greece; [email protected] 3 Global Pharmacovigilance, R&D Sanofi, 91385 Chilly-Mazarin, France; vid.stanulovic@sanofi.com 4 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 11521 Athens, Greece; [email protected] 5 Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 129 Vasilissis Sophias Avenue, 11521 Athens, Greece 6 Salpetriere Neuropsychiatric Clinic, 149 Papandreou Street, Metamorphosi, 14452 Athens, Greece * Correspondence: [email protected] Abstract: Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysio- logical mechanisms, including multiple sclerosis, migraines and neuromuscular disease. In addition, a great number of monoclonal antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these
    [Show full text]